Guggenheim reissued their buy rating on shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a report released on Friday. The firm currently has a $80.00 target price on the stock…...
SPORTSPERSPECTIVES.COM
READ MORE
|
The Karnataka Drugs and Pharmaceutical Manufacturers Association (KDPMA) sees that the Union government's effort to make a change in the criteria for classifying micro, small and medium enterprises (MSMEs) from investment in plant and machinery to annual turnover would make the process more transparent. It will align the MSMEs to the new tax regime revolving around GST (Goods & Services Tax)....
PHARMACEUTICAL EXECUTIVE
READ MORE
|
Bayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible approval later this year and a market clash with Pfizer/Astellas and Johnson & Johnson. The filing is based on data from the phase III ARAMIS trial of Orion-partnered darolutamide plus androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in the New England Journal of Medicine earlier th...
READ MORE
|
Despite resistance from top pharma companies, shareholders are set to vote this spring on resolutions seeking more information about potential links between executive pay and rising drug prices. Several drug industry players resisted the proxy vote, but the SEC ruled in favor of the Interfaith Center on Corporate Responsibility, which filed the resolutions last year. AbbVie, Amgen, Biogen, Bristol-Myers Squibb and Eli Lilly shareholders now have the right to vote on them, ICCR said. The group ha...
FIERCEPHARMA
READ MORE
|
The National Institute of Health and Care Excellence (NICE) has issued a positive Final Evaluation Determination (FED) recommending Cerdelga (eliglustat) as a first-line treatment for adults with the condition within its marketing authorisation, superseding a previous provisional rejection....
READ MORE
|
In a research paper published today by Nature Reviews Drug Discovery, AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity following significant revision of its approach and adoption of a '5R framework' - right target, right patient, right tissue, right safety, right commercial potential. The publication explains how adoption of the research unit's 5R framework has guided successful, efficient drug discovery and development whilst fi...
READ MORE
|